Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | High-dose methotrexate as CNS prophylaxis in DLBCL

Kate Cwynarski • 16 Jul 2020
EHA 2020
Aggressive & Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Methotrexate R-CHOP

Kate Cwynarski, MD, PhD, University College Hospital, London, UK, discusses data from a multicenter analysis evaluating the impact high-dose methotrexate as CNS prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kate Cwynarski

7:52
Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks
Kate Cwynarski et al. • 12 Dec 2022
3:31
Upcoming trials and agents in T-cell lymphoma
Gloria Iacoboni et al. • 10 Jun 2022
7:50
Updates from the lymphoma & CLL session: clinical trials, novel agents, and more
Andrew Davies et al. • 4 Apr 2022
14:09
Secondary CNS lymphoma: recent data and future approaches
Kate Cwynarski • 22 Jun 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals